Jasper Therapeutics
JSPR
57 hedge funds and large institutions have $47.8M invested in Jasper Therapeutics in 2025 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 15 increasing their positions, 18 reducing their positions, and 21 closing their positions.
181% more capital inflows, than outflows
Capital inflows: $30.2M | Capital outflows: $10.8M
152% more call options, than puts
Call options by funds: $315K | Put options by funds: $125K
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
11% less funds holding
Funds holding: 64 → 57 (-7)
11.29% less ownership
Funds ownership: 83.32% → 72.03% (-11%)
17% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 18
33% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Acorn Capital Advisors
New York
|
+$4.19M |
| 2 |
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$3.74M |
| 3 |
Woodline Partners
San Francisco,
California
|
+$3.15M |
| 4 |
Propel Bio Management
Los Angeles,
California
|
+$3.12M |
| 5 |
KCM
Kingdon Capital Management
New York
|
+$1.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Integral Health Asset Management
New York
|
-$3.27M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$2.97M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.14M |
| 4 |
Jane Street
New York
|
-$738K |
| 5 |
Goldman Sachs
New York
|
-$676K |
JSPR Hedge Fund Activity: Q3 2025 in Review
57 of the 7,661 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q3 2025, worth a combined $47.8M — down 31% from $69.5M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of JSPR and 14 opened new positions — a net loss of 7 holders — while 18 trimmed existing stakes and 15 added.
The largest buyer was Acorn Capital Advisors, opening a new position worth an estimated $4.19M. The largest seller was Integral Health Asset Management, exiting entirely with an estimated $3.27M sold.
- 57 institutional investors held Jasper Therapeutics (JSPR) as of Q3 2025, down from 64 in Q2 2025.
- Funds reported $47.8M of Jasper Therapeutics stock for Q3 2025, down 31% quarter-over-quarter.
- 14 funds opened new Jasper Therapeutics positions in Q3 2025 and 21 closed out, a net change of -7 holders.
- The largest Jasper Therapeutics buyer in Q3 2025 was Acorn Capital Advisors, an estimated $4.19M added.
- The largest Jasper Therapeutics seller in Q3 2025 was Integral Health Asset Management, an estimated $3.27M sold.
Based on aggregated 13F filings for Q3 2025.